{
  "trial_id": "NCT01404715",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age 18-45 years",
      "label": "met"
    },
    {
      "criterion": "Healthy participants",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or lactating woman (female subjects will have a urine pregnancy test at the screening visit)",
      "label": "triggers"
    },
    {
      "criterion": "Abnormal bone marrow function (leukocyte, neutrophil, or platelet counts outside the normal range)",
      "label": "triggers"
    },
    {
      "criterion": "History of hypersensitivity or allergic reaction to metformin or imatinib",
      "label": "triggers"
    },
    {
      "criterion": "Risk of congestive heart failure requiring pharmacologic treatment (medical history)",
      "label": "triggers"
    },
    {
      "criterion": "History of renal or hepatic dysfunction (e.g., CLcr <60mL/min, ALT >80U/L, AST>60 U/L)",
      "label": "triggers"
    },
    {
      "criterion": "Anemic (hemoglobin <12 g/dL)",
      "label": "triggers"
    },
    {
      "criterion": "Use of any medications (including over the counter products, herbal products, or mineral supplements) with the exception of a daily vitamin or oral contraceptives. In particular use of medications that are known to interfere with the pharmacokinetics of metformin and imatinib such as cimetidine, cetirizine, ketoconazole, procainamide, St. John's Wort, and testosterone are prohibited.",
      "label": "triggers"
    },
    {
      "criterion": "Subjects are undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute",
      "label": "triggers"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "24",
    "trial_id": "NCT01404715",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}